Receiving a denial for a claim related to a rare disease can feel devastating-but it is not the end of the road. Health plans are legally required to provide a clear reason for denial and a process to appeal. Because rare diseases often fall outside standard clinical guidelines or formularies, denials can happen due to a lack of established protocols, high treatment costs, or misclassification. However, the appeals process is designed to give you a structured path to challenge that decision, and your chances improve dramatically when you approach it strategically, document thoroughly, and leverage every legal protection available under ERISA and the Affordable Care Act (ACA).
Step 1: Understand Why the Claim Was Denied
Before you can appeal effectively, you need to know the exact reason for the denial. The insurer is required by law (under ERISA for employer-sponsored plans and state law for individual plans) to send you a formal denial letter. This letter must include:
- The specific reason(s) for the denial (e.g., “not medically necessary,” “experimental/investigational,” “out-of-network,” or “not a covered benefit”)
- The plan provision or exclusion cited
- The appeals process and deadlines
- Instructions for how to submit additional information
For rare diseases, the most common denial reason is “experimental or investigational” treatment or “lack of medical necessity” because FDA-approved treatments may not exist, or the plan’s guidelines were written for common conditions. Your appeal must address these precise points.
Step 2: Gather Critical Supporting Evidence
The strength of your appeal lies in the clinical evidence you provide. A generic letter from your doctor is rarely enough. Collect the following:
- Detailed letter from your treating specialist explaining why the denied treatment is medically necessary for your specific case, including peer-reviewed studies, case reports, or clinical trial data
- Medical records showing the disease progression, failed alternative treatments, and symptoms
- Published literature on the efficacy of the treatment for your rare condition-even if it’s from small studies or case series
- Support from patient advocacy organizations (e.g., National Organization for Rare Disorders, EveryLife Foundation) who often provide letters of medical necessity or research summaries
- A second opinion from a rare disease specialist at an academic medical center (many have dedicated rare disease clinics)
If the denial cites “lack of medical necessity” or “experimental,” consider submitting a formal “Medical Necessity Appeal” that includes a clinical rationale from an expert in the field. For rare disease treatments, plans sometimes require a peer-to-peer review-a direct conversation between your doctor and the plan’s medical director-which can overturn denials in real time.
Step 3: Follow the Formal Internal Appeals Process
Every health plan has a multi-level internal appeals process. You must exhaust these before pursuing external review. Here’s how to navigate it:
- File the first-level appeal within the time limit stated in your denial letter (typically 180 days for employer plans under ERISA). Write a formal appeal letter referencing the claim number, denial reason, and your evidence. Send it via certified mail or through the plan’s online portal with a confirmation receipt.
- If denied, file a second-level internal appeal-some plans offer this, especially for high-cost or rare disease claims. You may request an expedited appeal if delay could seriously jeopardize your health.
- Request a peer-to-peer review before or during the appeal. This is often the most effective step for rare disease claims because it allows your specialist to discuss your unique case directly with the plan’s physician, bypassing an algorithm or non-specialist review.
Throughout this process, keep a detailed log of every phone call, email, and letter. Note the names of representatives, dates, and what was discussed. Always meet every deadline-missing one can forfeit your appeal rights.
Step 4: If Internal Appeals Are Denied, Seek External Review
If the plan’s internal appeals process denies your claim, you have the right to an independent external review. Under the ACA, most non-grandfathered health plans (including many employer plans) must allow you to request an external review by an independent third-party organization. The plan’s decision during external review is binding. Steps include:
- File a request with the plan or state insurance department (the denial letter will explain how). You generally have 60 days from the final internal denial.
- Submit your case with all evidence-medical records, specialist letters, and research.
- The external reviewer has independent medical experts who evaluate your case against standard medical evidence, not just the plan’s internal guidelines.
For rare diseases, external reviewers are more likely to consider off-label or novel treatments if supported by credible evidence. Several states also have their own external review programs for fully insured plans-check with your state’s insurance commissioner.
Step 5: Elevate to Legal and Regulatory Options
If external review fails, you still have options, though they require more time and resources:
- File a complaint with the Employee Benefits Security Administration (EBSA) if your plan is ERISA-governed. EBSA investigates fiduciary violations, such as failure to properly consider evidence.
- Hire an attorney specializing in ERISA, health insurance, or rare disease litigation. Many law firms offer free consultations. They can argue that the denial is arbitrary and capricious or that the plan breached its fiduciary duty.
- Leverage patient assistance programs from pharmaceutical manufacturers, non-profits, or disease-specific foundations that may help cover treatment costs or provide legal aid.
- Consider a class action if the denial pattern affects many patients with the same rare disease-though this is a longer-term strategy.
Key Tips for Employees and Employers
From a benefits administration perspective, both employees and employers can take proactive steps to reduce the friction of rare disease claims:
- Employers: Review your plan’s medical necessity criteria and exclusions for rare diseases during annual enrollment. Consider adding a “rare disease rider” or working with a TPA that has expertise in rare conditions. Some self-funded employers include specific provisions for orphan drugs or high-cost specialty medications to avoid automatic denials.
- Employees: Document everything from day one-every medication, every provider visit, every denial letter. Get a “plan of care” from your specialist that explicitly states the treatment and why it’s essential. If you are enrolled in a health-to-wealth system like WellthCare that rewards preventive actions, note that early documentation of health status can support later appeals.
Why Persistence Pays Off
Rare disease denials are often overturned on appeal-studies show that about 40-60% of internal appeals succeed when strong clinical evidence is presented. The key is to treat the appeals process not as a clerical formality but as a rigorous, evidence-based negotiation. By understanding the system, building a robust case, and using every legal lever available, you can dramatically increase your odds of receiving the care you need. And for employers, creating a more transparent, aligned benefits ecosystem-one that rewards prevention and reduces waste-can help prevent these denials altogether, ensuring employees get care used first, before costly claims even begin.